CRISM Therapeutics Corporation
CRTX.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.00 | -0.12 | 0.49 |
| FCF Yield | -114.84% | -173.58% | -17.79% | -4.41% |
| EV / EBITDA | 0.79 | 0.42 | -7.71 | -20.69 |
| Quality | ||||
| ROIC | -39.46% | -52.37% | -10.77% | -6.97% |
| Gross Margin | 84.00% | 28.89% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.54 | 1.44 | 1.29 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 65.31% | 7.41% | -112.96% | 33.70% |
| Safety | ||||
| Net Debt / EBITDA | 2.27 | 1.13 | 1.60 | 3.79 |
| Interest Coverage | -52.91 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,646.25 | -4,117.00 | 0.00 | 0.00 |